非小细胞肺癌患者KRAS基因突变情况分析

Analysis of KRAS mutation in patients with non- small cell lung cancer

目的探讨非小细胞肺癌患者KRAS基因突变情况与临床特征间的相关性。方法收集经病理确诊的454例非小细胞肺癌患者的肿瘤组织,采用突变扩增阻滞系统(ARMS)技术检测组织标本中KRAS基因外显子2第12、13位密码子突变状态,分析基因突变与临床特征间的相关性。结果 454例非小细胞肺癌患者中有17例(3.7%)存在KRAS突变,第12位密码子共检出5种突变类型,分别是G12A(1.1%,5/454)、G12C(1.1%,5/454)、G12D(0.4%,2/454)、G12V(0.4%,2/454)、G12S(0.2%,1/454);第13位密码子检出1种突变类型,为G13D(0.4%,2/454)。KRAS基因突变率男性(6.2%,17/273)高于女性(0,0/181),两者差异有统计学意义(P<0.05)。结论非小细胞肺癌KRAS基因突变与患者性别有关,与年龄、病理组织类型、标本类型无关。ARMS技术操作简便,可以快速进行KRAS基因突变检测,有利于指导患者的个体化分子靶向治疗。

Objective To investigate the correlation between KRAS gene mutations and clinic features in patients with non- small cell lung cancer（NSCLC）. Methods Tumor specimens were obtained from 454 NSCLC patients. Mutaion analysis of KRAS（codons 12 and 13 of exon 2） was detected by amplification refractory mutation system（ARMS）.The correlation between gene mutation and clnicopathological characteristics were analyzed. Results KRAS mutations were identified in 17 cases（3. 7%） of NSCLC. Five types of mutation were detected in codon 12,including G12A（1.1%,5/454）,G12C（1.1%,5/454）,G12D（0.4%,2/454）,G12V（0.4%,2/454） and G12S（0.2%,1/454）. One type of mutation was detected in codon 13,G13D（0. 4%,2 /454）. KRAS mutation rate was significantly higher in males（6. 2%,17 /273） than in females（0%,0 /181; P 0. 05）. Conclusion ARMS is a fast and easy method in detecting KRAS mutations. In NSCLC patients,KRAS mutation is associated with gender,but not with the age,degree of differentiation or type of specimen.